Italia markets closed

Dow Jones
38.594,64
+5,48(+0,01%)
Nasdaq
17.721,14
+32,25(+0,18%)
Nikkei 225
38.102,44
-712,12(-1,83%)
EUR/USD
1,0725
+0,0016(+0,15%)
Bitcoin EUR
61.042,52
-1.115,93(-1,80%)
CMC Crypto 200
1.373,19
-14,97(-1,08%)

NBIX Oct 2024 145.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

11,30

0,00

(0,00%)

In data: 12:00PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat